SLC5A2 and diabetes mellitus: Because of its crucial role in glucose reabsorption in the kidney, SGLT2 has been identified as a therapeutic target for diabetes, as inhibition of glucose re-absorption leads to loss of glucose in the urine, which lowers blood glucose [8].